Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, randomized, double-blind, placebo-controlled trial evaluating the ability of risedronate [risedronic acid] to prevent skeletal related events in patients with metastatic prostate cancer commencing hormonal therapy: Hoosier Oncology Group GU02-41.

Next Previous
X
Search
Trial Profile

A phase III, randomized, double-blind, placebo-controlled trial evaluating the ability of risedronate [risedronic acid] to prevent skeletal related events in patients with metastatic prostate cancer commencing hormonal therapy: Hoosier Oncology Group GU02-41.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 14 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Cancer metastases; Prostate cancer
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 24 Oct 2023 Results comparing treatment regimens androgen deprivation therapy or docetaxel in the control or research arms in mHSPC were utilized from 13 trials which includes (NCT00002651, NCT00216060, NCT00079001, NCT00104715, NCT00268476, NCT00309985, NCT00685646) studies, presented at the 48th European Society for Medical Oncology Congress.
    • 13 Sep 2022 Results assessing whether castrate-resistant free survival and time to castrate-resistant disease are valid surrogates for OS from following clinical trials: NCT00002651, NCT00079001, NCT00104715, NCT00268476, NCT00309985, NCT00216060, ISRCTN38477744 and NCT00685646 presented at the 47th European Society for Medical Oncology Congress
    • 25 May 2016 Status changed from active, no longer recruiting to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top